Atlas Genetics elects Neil Butler chairman
This article was originally published in Clinica
Executive Summary
Neil Butler has joined UK point-of-care diagnostics company Atlas Genetics as chairman of its board of directors. Mr Butler's most recent role was CEO of Vivacta, which also specialised in POC diagnostics. Prior to this, he led Oxford Biosensors, an Oxford University spin-out offering hand-held medical diagnostics. Atlas, based in Bath, raised £16.9m ($27.3m) in series B financing last year (www.clinica.co.uk, 21 July 2011); the capital will be used to accelerate the launch of Atlas's first two tests – one for chlamydia alone and the other for chlamydia and gonorrhoea – that run on its Velox ultra-rapid POC platform.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.